USE OF mTOR INHIBITORS IN B CELL LEUKEMIA

mTOR 抑制剂在 B 细胞白血病中的应用

• 批准号: 7617848
• 负责人: STEPHAN A. GRUPP
• 金额: $ 32.1万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7617848
• 关键词: Acute Lymphocytic Leukemia; Apoptosis; B-Cell Development; B-Cell Lymphomas; B-Lymphocytes; Biological; Biological Assay; Blast Cell; Bone Marrow; Bone Marrow Transplantation; CCI-779; Cell Line; Cells; Child; Childhood; Childhood Acute Lymphocytic Leukemia; Clinical; Clinical Trials; Data; Disease; Effectiveness; Follow-Up Studies; Growth; Growth Factor; Human; Immunosuppressive Agents; In Vitro; Interleukin-7; Leukemic Cell; Lymphocyte Activation; Malignant Neoplasms; Malignant lymphoid neoplasm; Mature B-Lymphocyte; Modeling; Mus; NOD/SCID mouse; New Agents; Non-Hodgkin' s Lymphoma; Outcome; Pathway interactions; Patients; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Phase I Clinical Trials; Pilot Projects; Plants; Prophylactic treatment; Relapse; Resistance; Role; SDZ RAD; STAT3 gene; STAT5A gene; Sampling; Serum; Signal Pathway; Signal Transduction; Sirolimus; Surrogate Markers; TSLP gene; Therapeutic; Transgenic Mice; Translating; Translational Research; Transplantation; Xenograft procedure; base; design; experience; graft vs host disease; human FRAP1 protein; in vivo; inhibitor/antagonist; leukemia; leukemia/lymphoma; mTOR Inhibitor; mTOR Signaling Pathway; pilot trial; programs; research study; response; therapeutic target

DESCRIPTION (provided by applicant): Rapamycin, everolimus and CCI-779 are mTOR inhibitors (MTIs). This class of drugs was initially developed for use as an immunosuppressive after transplantation, but these drugs have long been recognized to have antiproliferative effects in cancer. MTIs may also inhibit mature B lymphocyte activation, and may inhibit the growth of mature B cell lymphomas. Precursor-B acute lymphoblastic leukemia is the most common childhood malignancy. Childhood ALL is successfully treated in 70% of patients, but in the 30% of patients who experience relapse, treatment is difficult, outcome uncertain and new agents are needed. Our preliminary data suggest that rapamycin is active in pre-B ALL. Rapamycin inhibits the growth of B precursor ALL lines in vitro, and we have also demonstrated activity in a murine model of leukemia/lymphoma. We hypothesize that MTIs may be effective drugs in the treatment of leukemia, and that one of the growth signals inhibited by these drugs in precursor B cells may be a signaling pathway activated by both IL-7 and TSLP. In order to evaluate MTI in ALL and the role of IL-7Ra signaling in this disease, we propose the following Specific Aims: 1) MTI powerfully inhibit ALL growth and induce apoptosis in ALL cells. We hypothesize that molecules activating IL-7Ra signaling, including TSLP, may be important in ALL growth and modulate the effect of MTI on ALL. We will: (a) Assess the effect of TSLP on ALL cells and the response to MTI; (b) assess the effect of TSLP on JAKs, STAT3, STAT5 and S6K1 in primary human ALL and compare it to the response to IL-7; and (c) use SCID/NOD expansion of primary ALL cells to investigate mTOR pathway targets in primary human ALL. 2) We will utilize SCID/NOD xenograft and stromal culture models to assess the impact of MTI on growth of primary human ALL cells obtained from COG clinical trials and pilot trials of MTI in ALL (aim 3). 3) As part of an overall investigational/translational plan, we will conduct: (a) a phase I trial of rapamycin in children with relapsed leukemia and non-Hodgkin lymphoma; (b) a pilot study of rapamycin as combined relapse/graft vs. host disease prophylaxis after bone marrow transplant for lymphoid malignancies. These trials are a critical part of the overall translational research plan and results from patient serum and biological samples will be used to refine the treatment approach, direct basic mechanistic experiments and design follow-up studies of this class of drugs in lymphoid malignancies. These studies will immediately translate to the designs of follow-up studies of these agents.

描述（由申请方提供）：雷帕霉素、依维莫司和CCI-779是mTOR抑制剂（MTIs）。这类药物最初是作为移植后的免疫抑制剂开发的，但这些药物长期以来一直被认为在癌症中具有抗增殖作用。MTIs还可以抑制成熟B淋巴细胞活化，并且可以抑制成熟B细胞淋巴瘤的生长。前体B急性淋巴细胞白血病是最常见的儿童恶性肿瘤。儿童ALL在70%的患者中得到成功治疗，但在30%的复发患者中，治疗困难，结果不确定，需要新的药物。我们的初步数据表明，雷帕霉素是活跃的前B ALL。雷帕霉素在体外抑制B前体ALL细胞系的生长，我们还在白血病/淋巴瘤小鼠模型中证实了其活性。我们推测MTIs可能是治疗白血病的有效药物，并且这些药物抑制前体B细胞的生长信号之一可能是由IL-7和TSLP激活的信号通路。为了评估ALL中的MTI和IL-7 Ra信号传导在这种疾病中的作用，我们提出了以下具体目的： 1)MTI可有效抑制ALL细胞生长并诱导细胞凋亡。我们推测激活IL-7 Ra信号传导的分子，包括TSLP，可能在ALL生长中很重要，并调节MTI对ALL的影响。我们将：（a）评估TSLP对ALL细胞的作用和对MTI的应答;（B）评估TSLP对原代人ALL中JAK、STAT 3、STAT 5和S6 K1的作用，并将其与对IL-7的应答进行比较;和（c）使用原代ALL细胞的SCID/NOD扩增来研究原代人ALL中的mTOR途径靶标。 2)我们将利用SCID/NOD异种移植和基质培养模型来评估MTI对从COG临床试验和MTI在ALL中的中试试验获得的原代人ALL细胞生长的影响（目的3）。 3)作为整体研究/转化计划的一部分，我们将进行：（a）雷帕霉素在复发性白血病和非霍奇金淋巴瘤儿童中的I期试验;（B）雷帕霉素作为淋巴恶性肿瘤骨髓移植后复发/移植物抗宿主病联合预防的初步研究。这些试验是整体转化研究计划的关键部分，患者血清和生物样本的结果将用于完善治疗方法，指导基本机制实验和设计此类药物在淋巴恶性肿瘤中的随访研究。这些研究将立即转化为这些药物的随访研究设计。

项目成果

A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).

• DOI: 10.1111/j.1365-2141.2009.07889.x
• 发表时间: 2009-12
• 期刊: British journal of haematology
• 影响因子: 6.5
• 作者: Pulsipher MA;Wall DA;Grimley M;Goyal RK;Boucher KM;Hankins P;Grupp SA;Bunin N
• 通讯作者: Bunin N

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

• DOI: 10.1056/nejmoa1215134
• 发表时间: 2013-04-18
• 期刊: The New England journal of medicine
• 作者: Grupp SA;Kalos M;Barrett D;Aplenc R;Porter DL;Rheingold SR;Teachey DT;Chew A;Hauck B;Wright JF;Milone MC;Levine BL;June CH
• 通讯作者: June CH